



## **130th MAINE LEGISLATURE**

## FIRST SPECIAL SESSION-2021

Legislative Document	No. 1539
H.P. 1144	House of Representatives, April 22, 2021

An Act To Provide Access to Fertility Care

Received by the Clerk of the House on April 20, 2021. Referred to the Committee on Health Coverage, Insurance and Financial Services pursuant to Joint Rule 308.2 and ordered printed pursuant to Joint Rule 401.

R(+ B. Hunt

ROBERT B. HUNT Clerk

Presented by Representative MADIGAN of Waterville. Cosponsored by Senator DAUGHTRY of Cumberland and Representatives: CRAVEN of Lewiston, EVANS of Dover-Foxcroft, Speaker FECTEAU of Biddeford, MEYER of Eliot, Senators: BRENNER of Cumberland, CARNEY of Cumberland.

1	Be it enacted by the People of the State of Maine as follows:
2	Sec. 1. 24-A MRSA §4320-Q is enacted to read:
3	<u>§4320-Q. Coverage for fertility services</u>
4 5	<b><u>1. Definitions.</u></b> As used in this section, unless the context otherwise indicates, the following terms have the following meanings.
6 7 8 9	A. "Experimental fertility procedure" means a procedure for which the published medical evidence is not sufficient for the American Society for Reproductive Medicine, its successor organization or a comparable organization to regard the procedure as established medical practice.
10 11 12	B. "Fertility diagnostic care" means procedures, products, medications and services intended to provide information about an individual's fertility, including laboratory assessments and imaging studies.
13 14 15	<u>C.</u> "Fertility patient" means an individual or couple with infertility or an individual unable to conceive as an individual or with a partner because the individual or couple does not have the necessary gametes for conception.
16 17 18 19 20 21 22 23 24	D. "Fertility preservation services" means procedures, products, medications and services, intended to preserve fertility, consistent with established medical practice and professional guidelines published by the American Society for Reproductive Medicine, its successor organization or a comparable organization for an individual who has a medical or genetic condition or who is expected to undergo treatment that may directly or indirectly cause a risk of impairment of fertility. "Fertility preservation services" includes the procurement and cryopreservation of gametes, embryos and reproductive material and storage from the time of cryopreservation for a period of 5 years. Storage may be offered for a longer period of time.
25 26 27 28	<u>E.</u> "Fertility treatment" means procedures, products, medications and services intended to achieve pregnancy consistent with established medical practice and professional guidelines published by the American Society for Reproductive Medicine, its successor organization or a comparable organization.
29 30 31	<u>F. "Gamete" means a cell containing a haploid complement of deoxyribonucleic acid that has the potential to form an embryo when combined with another gamete.</u> "Gamete" includes sperm and eggs.
32 33 34 35 36 37 38	G. "Infertility" means the presence of a demonstrated condition recognized by a provider as a cause of loss or impairment of fertility or a couple's inability to achieve pregnancy after 12 months of unprotected intercourse when the couple has the necessary gametes for conception, including the loss of a pregnancy occurring within that 12-month period, or after a period of less than 12 months due to a person's age or other factors. Pregnancy resulting in a loss does not cause the time period of trying to achieve a pregnancy to be restarted.
39 40	<b>2.</b> Required coverage. A carrier offering a health plan in this State shall provide coverage as provided in this subsection to an enrollee:
41	A. For fertility diagnostic care;
42	B. For fertility treatment if the enrollee is a fertility patient; and

1 <u>C. For fertility preservation services.</u>

<u>Coverage under this subsection must include evaluations, laboratory assessments,</u>
 medications and procedures intended to achieve pregnancy, including but not limited to the
 procurement of donor gametes. Coverage must be provided to the same extent that
 coverage is provided for other medical services or prescription drugs. Coverage under this
 subsection may not be denied to any enrollee who foregoes a particular fertility treatment
 or fertility preservation service if a provider determines that such fertility treatment or
 fertility preservation service is likely to be unsuccessful.

9 3. Limitations on coverage. A health plan that provides coverage for the services
 10 required by this section may include reasonable limitations to the extent that these
 11 provisions are not inconsistent with the following requirements.

A. A carrier may not impose deductibles, copayments, coinsurance, maximum benefits,
 waiting periods or other limitations that are different from those that are imposed on
 coverage for other services under the health plan or any limitations on coverage for
 prescribed fertility medication that are different from those that are imposed on other
 prescription medication.

- B. A carrier may not use any prior diagnosis or prior fertility treatment as a basis for
  excluding, limiting or otherwise restricting the availability of coverage required by this
  section.
- 20C. A carrier may not impose any limitations on coverage for any fertility services based21on an enrollee's use of donor gametes, donor embryos or surrogacy.

D. A carrier may not impose any limitations on coverage solely based on arbitrary
 factors, such as number of conception attempts, dollar amounts or age of an enrollee,
 or provide different benefits to or impose different requirements on a class of persons
 protected under Title 5, chapter 337 than those limitations placed on other enrollees.

E. Any limitations imposed by a carrier must be based on an enrollee's medical history and clinical guidelines. Any clinical guidelines used by a carrier must be maintained in written form and must be made available to an enrollee in writing upon request. Clinical guidelines developed by the American Society for Reproductive Medicine, its successor organization or a comparable organization may serve as a basis for a carrier's clinical guidelines. Making, issuing, circulating or causing to be made, issued or circulated any clinical guidelines that are based on data that are not reasonably current

33 or that do not cite with any specificity any reference relied upon constitutes an unfair
 34 or deceptive act or practice in the business of insurance pursuant to section 2152.

35 <u>4. Certain services not required.</u> This section does not require a carrier to provide
 36 <u>coverage for:</u>

- 37 <u>A. Any experimental fertility procedure; or</u>
- 38 B. Any nonmedical costs related to donor gametes, donor embryos or surrogacy.

39 5. Rules. The superintendent shall adopt rules as necessary to implement the
 40 requirements of this section. Rules adopted pursuant to this subsection are routine technical
 41 rules as defined in Title 5, chapter 375, subchapter 2-A.

42 **Sec. 2.** Application. This Act applies to all policies, contracts and certificates 43 executed, delivered, issued for delivery, continued or renewed in this State on or after

1	January 1, 2023. For purposes of this Act, all contracts are deemed to be renewed no later
2	than the next yearly anniversary of the contract date.

## 3 SUMMARY

This bill requires carriers offering health plans in this State to provide coverage for fertility diagnostic care, for fertility treatment if the enrollee is a fertility patient and for fertility preservation services. The requirements of the bill apply to health plans issued or renewed on or after January 1, 2023.